A Phase IIa Multi-Center Study of 18F-FDG PET, Safety, and Tolerability of AZD0530 in Mild Alzheimer's Disease
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 29 Jun 2017
At a glance
- Drugs Saracatinib (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 01 Dec 2016 Status changed from recruiting to active, no longer recruiting.
- 16 Jun 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.